Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?-Reference-Cited by-同舟云学术

Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?

Published:2018-11-15 Issue:3 Volume:38 Page:423-426
ISSN:0934-9723
Container-title:European Journal of Clinical Microbiology & Infectious Diseases
language:en
Short-container-title:Eur J Clin Microbiol Infect Dis

Author:

Troya Jesús,Ryan Pablo,Montejano Rocío,Cabello Alfonso,Cuevas Guillermo,Matarranz Mariano,Cañamares Irene,Solís Javier,Walther Luis Álvarez-Sala

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Link

http://link.springer.com/article/10.1007/s10096-018-3429-x/fulltext.html

Reference26 articles.

1. European Guidelines for treatment of HIV-infected adults in Europe. Guidelines version 9.0. European AIDS Clinical Society (EACS), October, 2017. Available at: http://www.eacsociety.org/files/guidelines_9.0-english.pdf . (Accessed August 2018)

2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services USA. Available at: https://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.pdf . (Accessed August 2018)

3. Raltegravir (Edurant®). Data sheet available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022145s004lbl.pdf (Accessed August 2018)

4. Rilpivirine (Issentress®). Data sheet available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022145s004lbl.pdf (Accessed August 2018)

5. Rasmussen TA, Jensen D, Tolstrup M, Nielsen US, Erlandsen EJ, Birn H, Ostergaard L, Langdahl BL, Laursen AL (2012) Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One 7(3):e32445. https://doi.org/10.1371/journal.pone.0032445